Laboratory parameters in MAESTRO-NASH

Liver Enzymes

Mean alanine aminotransferase Mean alanine aminotransferase
  • After initiating treatment with Rezdiffra, slight increases (<1.5x baseline) in ALT and AST were observed in the first 4 weeks. These values returned to baseline around 8 weeks after initiating treatment.2
  • Starting at Week 12 through Week 52, there was a trend of greater reductions from baseline in mean ALT and AST in the Rezdiffra groups as compared to the placebo group2,3
  • Reductions were most noticeable in patients with ALT≥30 U/L at baseline compared to patients with ALT<30 at baseline2,3
Mean aspartate aminotransferase Mean aspartate aminotransferase
  • After initiating treatment with Rezdiffra, slight increases (<1.5x baseline) in ALT and AST were observed in the first 4 weeks. These values returned to baseline around 8 weeks after initiating treatment.2
  • Starting at Week 12 through Week 52, there was a trend of greater reductions from baseline in mean ALT and AST in the Rezdiffra groups as compared to the placebo group2,3
  • Reductions were most noticeable in patients with ALT≥30 U/L at baseline compared to patients with ALT<30 at baseline2,3

Liver fat content2

Reductions in liver fat content in patients treated with both doses of Rezdiffra were observed at:

Learn about the demonstrated safety and tolerability profile of Rezdiffra2

See Safety
ALT=alanine transaminase; AST=aspartate aminotransferase; CAP=controlled attenuation parameter; MRI-PDFF=magnetic resonance imaging proton density fat fraction; NASH=nonalcoholic steatohepatitis; U/L=units per liter.
References:
  1. Data on file. REF-00630. Madrigal Pharmaceuticals, Inc.; June 2024.
  2. Rezdiffra. Prescribing Information. Madrigal Pharmaceuticals, Inc.
  3. Harrison SA et al. Nat Med. 2023;29(11):2919-2928.